Cyclerion Therapeutics (CYCN) Short term Debt (2019 - 2020)
Cyclerion Therapeutics (CYCN) posted Short term Debt of $286000.0 for Q4 2020, down 42.22% on a QoQ basis from $495000.0 in Q3 2020, and up 253.09% year-over-year from $81000.0 in Q1 2020.
Powered by 
Analysis
Cyclerion Therapeutics (CYCN) Short term Debt (2019 - 2020) Analysis & Trends
Cyclerion Therapeutics has reported Short term Debt for 2 years, with the latest figure at $286000.0 in Q4 2020.
- On a quarterly basis, Short term Debt rose 253.09% year-over-year to $286000.0 in Q4 2020; TTM through Dec 2020 was $286000.0, a 253.09% increase from a year earlier, with the FY2020 full-year figure at $286000.0, up 253.09% from the prior year.
- Short term Debt was $286000.0 for Q4 2020 at Cyclerion Therapeutics, down from $495000.0 in the prior quarter.
- The five-year high for Short term Debt was $1.9 million in Q2 2019, with the low at $59000.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn |
| 10 | Cyclerion Therapeutics | 15.70 Mn | 12.46 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 286,000.00 |
| Sep 30, 2020 | 495,000.00 |
| Jun 30, 2020 | 375,000.00 |
| Mar 31, 2020 | 59,000.00 |
| Dec 31, 2019 | 81,000.00 |
| Sep 30, 2019 | 187,000.00 |
| Jun 30, 2019 | 1.92 Mn |